Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors

(2010) Matthias Leisegang et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting

(2009) L. I. Sanchez-Abarca et al.   BLOOD

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

(2009) A Czibere et al.   BONE MARROW TRANSPLANTATION

Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

(2009) M Lübbert et al.   BONE MARROW TRANSPLANTATION

Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen

(2009) J. A. Dubovsky et al.   CLINICAL CANCER RESEARCH

Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency

(2009) Dan Lu et al.   VACCINE

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

(2008) K. Rezvani et al.   BLOOD

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

(2008) C. Quintarelli et al.   BLOOD

PRAME expression and clinical outcome of breast cancer

(2008) M T Epping et al.   BRITISH JOURNAL OF CANCER

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

(2008) Jennifer A. Wargo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

(2008) Sara J. Adair et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Development of Cellular Immune Responses against PAX5, a Novel Target for Cancer Immunotherapy

(2008) M. Yan et al.   CANCER RESEARCH

Epigenetic therapy of leukemia: An update

(2008) Nitin Jain et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma

(2008) Atsushi Natsume et al.   INTERNATIONAL JOURNAL OF CANCER